| Autor: |
Stefano Kim, Bruno Buecher, Thierry André, Marine Jary, François-Clément Bidard, François Ghiringhelli, Éric François, Julien Taieb, Denis Smith, Christelle de la Fouchardière, Jérôme Desramé, Emmanuelle Samalin, Aurélie Parzy, Nabil Baba-Hamed, Olivier Bouché, David Tougeron, Laëtitia Dahan, Farid El Hajbi, Marion Jacquin, Magali Rebucci-Peixoto, Laurie Spehner, Véronique Vendrely, Dewi Vernerey, Christophe Borg |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020) |
| Druh dokumentu: |
article |
| ISSN: |
1471-2407 |
| DOI: |
10.1186/s12885-020-06841-1 |
| Popis: |
Abstract Background Modified docetaxel, cisplatin, and 5-fluorouracil (mDCF) regimen has become a new standard for the treatment of metastatic or unresectable locally advanced recurrent squamous cell carcinoma of the anus (SCCA) after demonstrating improved efficacy (12-month PFS of 47%) in the Epitopes-HPV02 trial. Antibodies targeting the checkpoint inhibitor (CKI) programmed cell death protein-1 (PD1) have demonstrated the efficacy as monotherapies in second-line treatment of SCCA. The aim of this study is to evaluate the combination of atezolizumab and mDCF as first-line chemotherapy in a non-comparative multicentre randomized phase II study of advanced SCCA patients. Methods Patients with chemo-naive advanced histologically proven SCCA, metastatic or unresectable locally advanced recurrence, and Eastern Cooperative Oncology Group-performance status (ECOG-PS) |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
